RMC-5552 is a bi-steric inhibitor of mTORC1, the raptor-containing mTOR complex, which blocks its serine/threonine kinase activity and suppresses phosphorylation of 4EBP1 and S6K1. It is being studied in glioblastoma and recurrent glioblastoma.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
mTORC1/4EBP1
Drug type
Small molecule
Targets
mTORC1 (mechanistic target of rapamycin complex 1) (MTOR), eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1) (secondary target)
Mechanism
Inhibitor of mTORC1 (mechanistic target of rapamycin complex 1) (MTOR)
Pathways
PI3K/Akt/mTOR signaling, protein synthesis, cell cycle progression
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.